

9853 Pacific Heights Blvd. Suite D. San Diego, CA 92121, USA Tel: 858-263-4982

Email: info@abeomics.com

12-9156: Anti-IL17A (Cosentyx) (secukinumab biosimilar) mAb

Clonality: Monoclonal
Application: FACS
Reactivity: Human

Alternative Name: CTLA-8,CTLA8,IL-17,IL-17A,IL17

Isotype: lgG1

Description

Secukinumab (Cosentyx) is a biologic medication used to treat psoriatic arthritis, moderate to severe plaque psoriasis. Biologics are medicines that are human-made through genetic engineering techniques and closely related to a protein that occurs naturally in the body. Secukinumab blocks an inflammatory protein called IL-17, thus improving joint pain and swelling from arthritis and rash from psoriasis.

Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals.

Product Info

Amount : $50 \mu g / 100 \mu g$

Purification : Purified from cell culture supernatant by affinity chromatography

Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended

Storage condition: for use within a month, aliquot and store at -80°C (Avoid repeated freezing and

thawing). Lyophilized proteins are shipped at ambient temperature.

Application Note

FACS 1:100




Figure 1: Flow cytometry analysis with 1 $\hat{l}\frac{1}{4}$ g/mL Anti-IL17A (secukinumab biosimilar) mAb (12-9156) on Expi293 cells transfected with Human IL17A protein (Blue histogram) or Expi293 transfected with irrelevant protein (Red histogram).



9853 Pacific Heights Blvd. Suite D. San Diego, CA 92121, USA Tel: 858-263-4982

Email: info@abeomics.com




Figure 2: Coomassie Staining of SDS Page gel loaded with 5 μ g Anti-IL17A (consentyx) (secukinumab biosimilar) mAB.